<DOC>
	<DOCNO>NCT02452970</DOCNO>
	<brief_summary>The purpose study see investigational drug , RRx-001 , epigenetic agent , turn number beneficial gene tumor silence , resensitize tumor ( ) , word make it/them re-respond gemcitabine cisplatin , , hopefully , translate longer lifespan . The name open-label study , mean patient know treatment receive , EPIC , hybrid combination EPIgenetic mechanism action RRx-001 Cholangiocarcinoma . The study treatment divide two stage . During first stage , patient receive RRx-001 , administer intravenously weekly , fixed time period six week . At time second stage start cisplatin gemcitabine reintroduce long tumor respond determine whether resensitization occur . The primary objective clinical trial evaluate progression-free survival ( PFS ) patient 9 week reintroduction gemcitabine cisplatin .</brief_summary>
	<brief_title>RRx-001 Second Line Treatment Advanced Cholangiocarcinoma Prior Readministration First-Line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis biliary tract adenocarcinoma/cholangiocarcinoma Must locally advance distant metastatic disease surgically curable Failed firstline chemotherapy Age â‰¥ 18 year Life expectancy least 12 week ( 3 month ) Performance status 0 1 Adequate liver , kidney , bone marrow function Symptomatic metastatic brain meningeal tumor Investigational compound within 4 week enrollment History need permanently discontinue prior gemcitabine/ cisplatin regimen reason progression ( i.e . toxicity ) Any medical condition , investigator 's opinion , make patient unsuitable participation Pregnant nursing Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result Albumin &lt; 2.8 Uncontrolled clinically relevant ascites Absolute contraindication MRI image intracorporeal metal pacemaker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>